FDA orders 4 firms to stop selling unapproved codeine products

10/13/2009 | United Press International

The FDA sent warning letters prohibiting Glenmark Generics, Lehigh Valley Technologies, Cerovene and Dava International from marketing unapproved codeine sulfate tablets as a treatment for pain. The agency gave manufacturers 90 days to halt production, and distributors have 180 days to stop shipment.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC